- Home
- GROW vs ATHA Comparison
GROW vs ATHA Comparison
Compare GROW & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | ATHA |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.2M | 26.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GROW | ATHA |
|---|---|---|
| Price | $2.49 | $7.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 34.4K | ★ 3.2M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $8,546,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $2.20 |
| 52 Week High | $2.78 | $8.36 |
Technical Indicators
Market Signals| Indicator | GROW | ATHA |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 64.24 |
| Support Level | $2.45 | $6.41 |
| Resistance Level | $2.55 | $7.64 |
| Average True Range (ATR) | 0.07 | 0.74 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 64.86 | 43.47 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.